Invivyd, Inc. · NASDAQ:IVVD
Invivyd — World Vaccine Congress Washington 2026
29 slides from Invivyd's conference presentation, March 2026
Slide 1: Developing mAb therapies to keep pace with rapidly evolving viral threats
Developing mAb therapies to keep pace with rapidly evolving viral threats World Vaccine Congress Washington 2026 © 2026 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: Why Monoclonal Antibodies (mAbs) at WVC?
WHY MONOCLONAL ANTIBODIES (MABS) AT WVC? A lack of choice is driving a growing gap in protection against the threat of infectious disease Even the best vaccines have not fully contained the public health burden of any pathogens except smallpox Invivyd is committed to developing effective treatments
Slide 4: Key challenges to broad mAb usage do not differ from those faced by vaccines
KEY CHALLENGES TO BROAD MAB USAGE DO NOT DIFFER FROM THOSE FACED BY VACCINES SCALE ACCESS PATHOGEN STRAIN VARIATION
Slide 5: Predictive trends in Spike RBD polymorph data
Predictive trends in Spike RBD polymorph data Mutations that are ‘explored’ by the virus are more likely to dominate in the future
Slide 6: Mutagenic space within 1 nt change from Wuhan-H1
Mutagenic space within 1 nt change from Wuhan-H1
Slide 7: AA changes resulting from single nucleotide changes observed in circulating variant
AA changes resulting from single nucleotide changes observed in circulating variant 2 years after Wuhan-H1emergence
Slide 8: The defining mutations of LP.8.1 emerged from single nucleotide changes
The defining mutations of LP.8.1 emerged from single nucleotide changes LP.8.1 is differentiated from its KP.1.1 parent at 4 positions in the spike protein LP.8.1 KP.1.1 (KP.1.1.3.8.1) S position amino amino codon codon (genome position) acid acid 186 F TTC L TTA (22118-22120) All four of the defini
Slide 9: Polymorphs at the amino acid and nucleotide level
Polymorphs at the amino acid and nucleotide level WT BA.2.86
Slide 10: BA.3.2 RBD Amino Acid Polymorph Graphs
BA.3.2 RBD AMINO ACID POLYMORPH GRAPHS Position 326 Position 339 Position 348 Position 435 100% 100% 100% 100% G339H Proportion (% of total sequences) Proportion (% of total sequences) Proportion (% of total sequences) Proportion (% of total sequences) I326V G339D A348T A435S 10% 10% 10% 10% I326S A
Slide 11: Single nucleotide polymorph graphs: pemivibart epitope
Single nucleotide polymorph graphs: pemivibart epitope
Slide 12: Further filtering based on single nucleotide substitution bias
Further filtering based on single nucleotide substitution bias in SARS-CoV-2 Pemivibart DMS Escape Determinants in the BA.2.86 Background -- mutations accessible from a single C>T, G>T, or G>A nucleotide mutation -- SARS-CoV-2 heavily favors C>T and G>T nucleotide mutations, which enables further fi
Slide 13: SARS-CoV-2 Spike RBD Residue Plasticity Index (RPI)
SARS-COV-2 Spike Receptor Binding Domain (RBD) Residue Plasticity Index (RPI) Poll sequence data for weekly mutation proportions For all mutations, populate missing dates with proportion = 0 Calculate the absolute rate of change for each mutation • The RPI is based on the polymorph Isolate date rang
Slide 14: RPI measurements of Spike RBD residues
RPI measurements of Spike RBD residues Position 504 RPI Position 332 RPI Position 452 RPI
Slide 15: The monthly RBD RPI shows evolutionary hotspots as they emerge
The monthly RBD RPI shows evolutionary hotspots as they emerge Polymorphic Plasticity low high 0 6
Slide 16: Pemivibart epitope RPI has remained stable in the post-omicron era
Pemivibart epitope RPI has remained Stable in the post-omicron era pemivibart Pemivibart epitope derived from 5 Å residue cloud as modeled bound to the BA.5 RBD. Polymorphic Plasticity low high 0 6 -Data through Sept 2025
Slide 17: CDC COVID Data Tracker through March 13th shows XFG in dominant position
CDC COVID DATA TRACKER THROUGH MARCH 13TH SHOWS XFG IN DOMINANT POSITION • XFG at 23% • XFG.1.1 at 21% • XFG.14.1 at 10% • Accessed 3/17/26: https://www.cdc.gov/covid/php/variants/variants-and-genomic-surveillance.html
Slide 18: Internal analysis confirms XFG* is the likely leading variant clade in US
INTERNAL ANALYSIS CONFIRMS THAT XFG* IS THE LIKELY LEADING VARIANT CLADE IN US BASED ON BIOBOT WASTEWATER DATA US Invivyd-Biobot Wastewater Data (14 day rolling mean) 1 graph_lineage On a national scale, for BA.3.2* samples collected as of XEC* XFG.14.1* JN.1* March 5th, 2026: LP.8.1* NB.1.8.1* 0.8
Slide 19: Pemivibart epitope and neutralization potency have remained stable
Pemivibart epitope and neutralization potency have remained stable
Slide 20: Pemivibart and VYD2311 epitope and neutralization potency have remained stable
Pemivibart and VYD2311 epitope and neutralization potency have remained stable
Slide 21: Measles Virus Background
MEASLES VIRUS BACKGROUND • The Measles Virus (MeV) is an RNA Morbillivirus Measles • There are 24 strains of MeV divided into 8 clades: A-H • Transmission occurs through respiratory droplets and is highly infectious • Symptoms include fever, coughing, malaise, and a rash • Complications occur in ~30
Slide 22: Measles Virus Wastewater Surveillance
22 MEASLES VIRUS WASTEWATER SURVEILLANCE Biobot • Quantitative measurement, but no genotyping • ddPCR for non-vaccine strain H gene • New methods for complete genome sequencing from wastewater are now being explored.
Slide 23: Current Measles Virus Variants
CURRENT MEASLES VIRUS VARIANTS FUSION (F) CONSERVATION • B3 and D8 genotypes have dominated for several years Global B3 D8 U.S. B3 D8 Current outbreak in South Carolina • 139 complete F sequences from the past 6 months, all of genotype D8 • 125 (90%) are identical • 14 carry a single amino acid chan
Slide 24: Measles Virus Surface Proteins
MEASLES VIRUS SURFACE PROTEINS • Like PIV and MuV, the MeV genome encodes for two surface proteins: Fusion (F) and Hemagglutinin (H) • The F-protein is the trimeric fusion protein responsible for viral membrane fusion • The H-protein is responsible for cell adhesion • Antibodies isolated from vaccin
Slide 25: The MeV-F Protein
THE MEV-F PROTEIN • MeV-F is responsible for viral-cell fusion in measles • It is a trimeric protein similar to RSV-F, with a pre-fusion and post-fusion conformation • The MeV-F0 protein is cleaved by Furin (red arrow) into F2 and F1 − There is a conserved fusion peptide in F1 • To produce a stable
Slide 26: Measles De Novo Discovery – Neutralization Assays
MEASLES DE NOVO DISCOVERY – NEUTRALIZATION ASSAYS • Invivyd De Novo B Cell discovery begins with human donor PBMC’s, often convalesced from or vaccinated to the target pathogen • Biospecimen are prepared and enriched for antibody producing B cells with binding activity to the viral antigens • Antibo
Slide 27: Hit to Lead Library of Random and Site-Directed Mutations
HIT TO LEAD LIBRARY OF RANDOM AND SITE-DIRECTED MUTATIONS • Top hits from high throughput yeast progress to mammalian expression for screening in a suite of functional and biophysical assays: − Pseudoviral neutralization assays • Evaluating CD46 and CD150 pseudoviral entry − Authentic virus neutrali
Slide 28: Invivyd Antibody Development Programs
INVIVYD ANTIBODY DEVELOPMENT PROGRAMS SARS-CoV-2 VYD2311 RSV Measles HMPV Borrelia Lyme PIV Pertussis Rubella Mumps
Slide 29: Acknowledgements
ACKNOWLEDGEMENTS • Tyler Starr Lab at University of Utah • Ian Wilson Lab at Scripps Research • Kristian Andersen Lab at Scripps Research • Invivyd Variant Monitoring • Invivyd Antibody Discovery • Invivyd Virology